CN102532250A - 具有抗肿瘤活性的化合物甘西鼠尾草酮a,其制备方法和其应用 - Google Patents
具有抗肿瘤活性的化合物甘西鼠尾草酮a,其制备方法和其应用 Download PDFInfo
- Publication number
- CN102532250A CN102532250A CN2011104317252A CN201110431725A CN102532250A CN 102532250 A CN102532250 A CN 102532250A CN 2011104317252 A CN2011104317252 A CN 2011104317252A CN 201110431725 A CN201110431725 A CN 201110431725A CN 102532250 A CN102532250 A CN 102532250A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- formula
- pharmaceutically acceptable
- ketone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 230000000259 anti-tumor effect Effects 0.000 title description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 4
- 201000005202 lung cancer Diseases 0.000 claims abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 4
- 241000687941 Salvia przewalskii Species 0.000 claims description 35
- 235000008202 Salvia przewalskii Nutrition 0.000 claims description 35
- 150000002576 ketones Chemical class 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 229960001866 silicon dioxide Drugs 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 6
- -1 micropill Substances 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 238000001647 drug administration Methods 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 208000019838 Blood disease Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000012053 oil suspension Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000001472 cytotoxic effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 125000002298 terpene group Chemical group 0.000 abstract 1
- 235000007586 terpenes Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- CSMFGPHUQWSIGM-RDFLCCBXSA-N przewalskone Natural products C1=CC2=C(C)C=CC=C2C2=C1C(O[C@@H]1OC=3C=4C[C@]56[C@H](C(CCC5)(C)C)C[C@H](O6)C=4C=C(C=3O[C@@]11C)C(C)C)=C1C(=O)[C@]2(CC(C)=O)O CSMFGPHUQWSIGM-RDFLCCBXSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 241001529246 Platymiscium Species 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 241001072909 Salvia Species 0.000 description 4
- 235000017276 Salvia Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229930004069 diterpene Natural products 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- OGLCDGGZWDKTDJ-FTRWYGJKSA-N (1S,9S,11S)-12,12-dimethyl-6-propan-2-yl-16-oxatetracyclo[7.6.1.01,11.03,8]hexadeca-3(8),6-diene-4,5-dione Chemical compound C1CCC(C)(C)[C@@H]2C[C@H]3C(C=C(C(C4=O)=O)C(C)C)=C4C[C@]21O3 OGLCDGGZWDKTDJ-FTRWYGJKSA-N 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 244000295490 Salvia japonica Species 0.000 description 2
- 235000005794 Salvia japonica Nutrition 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- 241000331777 Arisaema balansae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- WQYKPUPMMFGHQW-UHFFFAOYSA-N danshenol A Natural products C1=CC2=C(C)C=CC=C2C(C(O)(CC(C)=O)C2=O)=C1C1=C2C(C)CO1 WQYKPUPMMFGHQW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110431725.2A CN102532250B (zh) | 2011-11-07 | 2011-12-21 | 具有抗肿瘤活性的化合物甘西鼠尾草酮a,其制备方法和其应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110349495.5 | 2011-11-07 | ||
CN201110349495 | 2011-11-07 | ||
CN201110431725.2A CN102532250B (zh) | 2011-11-07 | 2011-12-21 | 具有抗肿瘤活性的化合物甘西鼠尾草酮a,其制备方法和其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102532250A true CN102532250A (zh) | 2012-07-04 |
CN102532250B CN102532250B (zh) | 2013-09-25 |
Family
ID=46340405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110431725.2A Expired - Fee Related CN102532250B (zh) | 2011-11-07 | 2011-12-21 | 具有抗肿瘤活性的化合物甘西鼠尾草酮a,其制备方法和其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102532250B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104844616A (zh) * | 2015-03-27 | 2015-08-19 | 云南民族大学 | 一种Icetexane型C18降二萜类化合物及其制备方法和应用 |
CN110507611A (zh) * | 2019-08-23 | 2019-11-29 | 中国医科大学 | 一种鼠尾草酸纳米乳口服液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020077352A1 (en) * | 2000-08-03 | 2002-06-20 | Sucher Nikolaus J. | N-methyl-D-aspartate receptor antagonists |
CN101531644A (zh) * | 2009-02-18 | 2009-09-16 | 沈阳药科大学 | 芫花中新的瑞香烷型二萜类化合物及其制备方法和用途 |
CN101600420A (zh) * | 2006-11-24 | 2009-12-09 | 帝斯曼知识产权资产管理有限公司 | 三环二萜及其衍生物用于治疗、辅助治疗或预防炎性病症和/或关节病症的用途 |
-
2011
- 2011-12-21 CN CN201110431725.2A patent/CN102532250B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020077352A1 (en) * | 2000-08-03 | 2002-06-20 | Sucher Nikolaus J. | N-methyl-D-aspartate receptor antagonists |
CN101600420A (zh) * | 2006-11-24 | 2009-12-09 | 帝斯曼知识产权资产管理有限公司 | 三环二萜及其衍生物用于治疗、辅助治疗或预防炎性病症和/或关节病症的用途 |
CN101531644A (zh) * | 2009-02-18 | 2009-09-16 | 沈阳药科大学 | 芫花中新的瑞香烷型二萜类化合物及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
杨阳等: "甘西鼠尾草化学成分及药理作用研究进展", 《中药材》, vol. 31, no. 5, 31 May 2008 (2008-05-31), pages 787 - 790 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104844616A (zh) * | 2015-03-27 | 2015-08-19 | 云南民族大学 | 一种Icetexane型C18降二萜类化合物及其制备方法和应用 |
CN110507611A (zh) * | 2019-08-23 | 2019-11-29 | 中国医科大学 | 一种鼠尾草酸纳米乳口服液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102532250B (zh) | 2013-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khalil et al. | A new anti-Helicobacter pylori juglone from Reynoutria japonica | |
Li et al. | The bioavailability of ginkgolides in Ginkgo biloba extracts | |
CN102532250B (zh) | 具有抗肿瘤活性的化合物甘西鼠尾草酮a,其制备方法和其应用 | |
Yeh et al. | Naturally occurring cytotoxic [3′→ 8 ″]-biflavonoids from Podocarpus nakaii | |
Aboalola et al. | Toxicological study of various crude extracts of Hyoscyamus gallagheri native to Oman | |
Yuzbasioglu et al. | Cytotoxic compounds from endemic Arnebia purpurea | |
CN100413868C (zh) | 分离自藤黄树脂并具有抑制肿瘤/癌细胞生长活性的化合物以及包含其的药物组合物 | |
CN106619652A (zh) | 阔叶丰花草三萜化合物的制备方法及其在制备糖苷酶抑制剂药物中的应用 | |
CN103288614A (zh) | 具有抗肿瘤活性的单环间苯三酚类化合物及其药物组合物 | |
CN114573456A (zh) | 一种贝壳杉烷型二萜化合物及其制备方法和应用 | |
CN101721434B (zh) | 一种阿里红有效组分及其制备方法和用途 | |
CN111529515B (zh) | 12,15-二氧-α-蛇床烯在制药中的应用 | |
CN109111462A (zh) | 一种鼠尾草甲素及其制备方法以及包含鼠尾草甲素的药物 | |
Bradacs | Ethnobotanical survey and biological screening of medicinal plants from Vanuatu | |
Hijazi et al. | Anticancer activity of abietane diterpenoids from Salvia libanoticum grown in Lebanon | |
Adione et al. | Detection, isolation and identification of more bioactive compounds from Fusarium equiseti, an endophytic fungus isolated from Ocimum gratissimum | |
CN109705183A (zh) | 臭七次生代谢物及其药物组合物与其制备方法和其应用 | |
CN102391353B (zh) | 割舌树内酰胺a及其制备方法和在药物上的应用 | |
CN107082780A (zh) | 一种具有吡咯骈异喹啉结构的生物碱及其制备方法与应用 | |
CN112979740B (zh) | 一种睡茄交酯ⅰ类化合物及其提取方法和应用 | |
CN113968780B (zh) | 白木香素a和b及其制备方法与其药物组合物和应用 | |
CN115490660B (zh) | 南牡蒿内酯a-d及其药物组合物和其应用 | |
CN104610207B (zh) | 大黄栀子素a及其制备方法和在药物上的应用 | |
CN106966969B (zh) | 一种生物碱化合物及其制备方法和用途 | |
CN108530505A (zh) | 一种黄酮苷类化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120704 Assignee: Beijing Zhongke Wenqing Technology Development Co.,Ltd. Assignor: KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES Contract record no.: X2022530000007 Denomination of invention: Compound gancyrone A with antitumor activity, its preparation method and its application Granted publication date: 20130925 License type: Common License Record date: 20220831 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130925 |